Skip to main content

Advertisement

SpringerLink
Log in

Hypofractionated whole breast irradiation in association with hypofractionated or normofractionated boost to the tumor bed in early breast cancer: tolerance and efficacy analysis

  • RESEARCH ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

The boost to the tumor bed improves local control in breast cancer and it is an important part of the breast conserving therapy. However, information about the use of a hypofractionated boost is sparse, thus further studies are needed. We conducted a retrospective study with the aim of comparing hypofractionated boost (HB) and normofractionated boost (NB) on skin toxicity and local control.

Materials and methods

A total of 96 women with early breast cancer undergoing breast-conserving surgery and hypofractionated whole breast irradiation (WBI) were retrospectively analyzed divided into hypofractionated boost group and conventional fractionation boost group. Forty-nine patients were treated with NB with 16 Gy in 8 fractions and 47 patients were treated with HB with 13.35 Gy in 5 fractions. We examined acute and chronic toxicity with CTCAE version 5.

Results

The median follow-up was 49.5 months (26–67). Median age was 57 years (36–82). Sixty-six patients (68.7%) were younger than 60 years at the time of boost and 30 (31.2%) were older than 60 years who received the boost due to poor prognostic factors. No differences were found between the two groups in terms of patient, tumor or treatment characteristics. Grade 2 acute skin toxicity was 6.3% in the NB group and 4.2% in the HB group. Chronic skin induration was 4.2% in the NB group and 1% in the HB group. They did not show grade 3 skin toxicity. There were also no differences in acute or late skin toxicity between the two groups. No local recurrences were evidenced.

Conclusions

Hypofractionated WBI associated with HB treatment is a viable option in the management of conservative breast therapy given the good tolerance and similar local control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. Lancet. 2011;378:1707–16.

    Article  Google Scholar 

  2. Haviland JS, Owen JR, Dewar JA, Agrawal KR, Barrett J, Barrett-Lee JP, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94.

    Article  PubMed  Google Scholar 

  3. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.

    Article  CAS  PubMed  Google Scholar 

  4. Jones HA, Antonini N, Hart AA, Peterse JL, Horiot J-C, Collin F, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009;27:4939–47.

    Article  PubMed  PubMed Central  Google Scholar 

  5. START Trialists Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–41.

    Article  Google Scholar 

  6. START Trialists Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;4:331–41.

    Google Scholar 

  7. Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Janson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75(1):9–17.

    Article  PubMed  Google Scholar 

  8. Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, et al. Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. Pract Radiat Oncol. 2018;8:145–52.

    Article  PubMed  Google Scholar 

  9. Lihu G, Wei D, Rongrong F, Hongfeng L, Jingyi S, Yetan S, et al. Comparing hypofractionated with conventional fractionated radiotherapy after breast-conserving surgery for early breast cancer a meta-analysis of randomized controlled trials. Front Oncol. 2021;11:753209.

    Article  Google Scholar 

  10. Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. European organisation for research and treatment of cancer radiation oncology and breast cancer groups whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer. Lancet Oncol. 2015;16(1):47–56.

    Article  PubMed  Google Scholar 

  11. Immink JM, Putter H, Bartelink H, Cardoso JS, van der Hulst-Vijgen MH, V; Noordijk E. M., et al. Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC “boost versus no boost” trial. Ann Oncol. 2012;23:2591–8.

    Article  CAS  PubMed  Google Scholar 

  12. Collette S, Collette L, Budiharto T, Horiot J-C, Poortmans PM, Struikmans H, et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer - a study based on the EORTC trial 22881–10882 “boost versus no boost.” Eur J Cancer. 2008;44:2587–99.

    Article  PubMed  Google Scholar 

  13. Gulstene S, Raziee H. Radiation boost after adjuvant whole breast radiotherapy: does evidence support practice for close margin and altered fractionation? Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.00772.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Lee SW, Kim YJ, Shin KH, Kim K, Chie EK, Han W, et al. A comparative study of daily 3-Gy hypofractionated and 1.8-Gy conventional breast irradiation in early-stage breast cancer. Medicine. 2016;95:e3320.

    Article  PubMed  PubMed Central  Google Scholar 

  15. De Felice F, Ranalli T, Musio D, Lisi R, Rea F, Caiazzo R, et al. Relation between hypofractionated radiotherapy, toxicity and outcome in early breast cancer. Breast J. 2017;23:563–8.

    Article  PubMed  Google Scholar 

  16. Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, et al. Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol. 2015;1:931–41.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kim JY, Jung SY, Lee S, Kang H-S, Lee ES, Park IH, et al. Phase 2 trial of accelerated, hypofractionated whole-breast irradiation of 39 Gy in 13 fractions followed by a tumor bed boost sequentially delivering 9 Gy in 3 fractions in early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2013;87:1037–42.

    Article  PubMed  Google Scholar 

  18. Janssen S, Glanzmann C, Lang S, Verlaan S, Streller T, Linsenmeier C, et al. Hypofractionated radiotherapy for breast cancer including risk-adapted boost: update on tolerance and efficacy of an accelerated START a regime. Anticancer Res. 2016;36:2513–22.

    CAS  PubMed  Google Scholar 

  19. Ahlawat S, Haffty BG, Goyal S, Kearney T, Kistein L, Chen C, et al. Short-course hypofractionated radiation therapy with boost in women with stages 0 to IIIa breast cancer: a phase 2 trial. Int J Radiat Oncol Biol Phys. 2016;94:118–25.

    Article  PubMed  Google Scholar 

  20. Shuhong Z, Yi L, Fengxian H, Xin C, Ximing C, Jiao Y, et al. The long-term outcome of adjuvant hypofractionated radiotherapy and conventional fractionated radiotherapy after breast-conserving surgery for early breast cancer: a prospective analysis of 107 cases. J Thorac Dis. 2017;9(10):3840–50.

    Article  Google Scholar 

  21. Shu-Lian W, Hui F, Chen H, Yong-Wen S, Wei-Hu W, Jing J;, et al. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China. J Clinic Oncol. 2020;38(31):3604–14.

    Article  Google Scholar 

Download references

Funding

This publication was prepared without any external source of funding should appear.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology of Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain

    Gabriela Oses, Tanny Daniela Barreto, Carla Cases, Diego Muñoz-Guglielmetti, Gabriela Antelo & Meritxell Mollà

  2. Department of Clinical Foundations, University of Barcelona, Barcelona, Spain

    Meritxell Mollà

Authors
  1. Gabriela Oses
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanny Daniela Barreto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carla Cases
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Diego Muñoz-Guglielmetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gabriela Antelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Meritxell Mollà
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriela Oses.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval (Research involving human participants and/or animals)

Ethical approval: HCB/2020/0962.

Informed consent

All the patients signed informed consent form.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oses, G., Barreto, T.D., Cases, C. et al. Hypofractionated whole breast irradiation in association with hypofractionated or normofractionated boost to the tumor bed in early breast cancer: tolerance and efficacy analysis. Clin Transl Oncol 25, 2419–2426 (2023). https://doi.org/10.1007/s12094-023-03124-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-023-03124-6

Keywords

Search

Navigation